Syngene International Limited reported an 11% year-on-year increase in revenue from operations to ₹875 crore for the first quarter of FY26. The company's reported profit after tax (PAT) before ...

Biosimilars and Biologics Market Driven by aging populations and patent cliffs, the biosimilars & biologics market will grow from ~$531B in ...

Initially, Dr Reddy's will focus on launching the generic semaglutide in Canada, India, Brazil, Turkey, and other emerging ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

With over three decades of experience across India, ASEAN, and Australia, Deepali Naair brings deep expertise in brand ...

Biocon Biologics appoints Deepali Naair as Global Head of Brand & Corporate Communications. She brings 30+ years experience ...

On Wednesday, 2005 stocks advanced, 2025 declined and 168 remained unchanged on Bombay Stock Exchange with advance decline ...

Naair will lead Biocon Biologics' global brand and corporate communications strategy as part of its executive team, reporting ...

This article highlights the top B.Tech Biotechnology colleges in India for 2025, detailing their course durations, fees, and ...

Syngene's margins narrowed on a sequential basis. Apart from margins, Syngene's revenue and EBITDA are also lower by 14.1% ...